Nova Leap Health Corp. Posts Best Financial Performance in Company History with Record Q3 2025 Results

Executive Summary

• Nova Leap Health Corp. reported record Q3 2025 consolidated revenues of $8.26 M, a 3% increase versus Q2 2025 and 29% versus Q3 2024.
• Adjusted EBITDA reached $670,706, up 16.1% from the prior quarter and 76.9% year‑over‑year, marking a new performance benchmark for the company.
• Net income turned positive at $426,171 after a net loss in Q2 2025, while cash on hand was $1.57 M and the company retained full access to its revolving credit facility and additional acquisition financing of up to $4.69 M.

Key Details

• Revenue: $8,264,326 (Q3 2025) – +3% vs Q2 2025; +29% vs Q3 2024.
• Adjusted EBITDA: $670,706 (Q3 2025) – +16.1% vs Q2 2025; +76.9% vs Q3 2024.
• Gross profit margin: 39.6% of revenue in Q3 2025 (vs 40.2% in Q2 2025 and 38.0% in Q3 2024).
• Operating cash flow: $418,553 generated in Q3 2025 (+$68,114 vs Q2 2025).
• Net income: $426,171 (Q3 2025) – reversal from net loss of $484,008 in Q2 2025 and $207,871 loss in Q3 2024.
• Liquidity: Cash balance $1,571,716 as of Sept 30 2025; unutilized revolving credit facility $1,077,509 (CAD 1.5 M).
• Leverage: Total demand loans & promissory notes $2,300,800; leverage ratio 1.18× TTM Adjusted EBITDA ($1,950,620).
• Acquisition financing: Access to up to $4,691,000 under existing credit agreement for future acquisitions.
• Segment performance: Record revenues, gross margins and Adjusted EBITDA reported for both Canadian and U.S. operating segments (specific segment dollar amounts not disclosed).
• Insider ownership: Increased during the quarter, reinforcing alignment with shareholders.

Notable Quotes

“Q3 was another record‑breaking quarter for Nova Leap… we have established a new level of performance materially higher than before.” – Chris Dobbin, President & CEO

All figures are presented in U.S. dollars unless otherwise noted.